StocksFundsScreenerSectorsWatchlists
DNA

DNA - Ginkgo Bioworks Holdings, Inc. Stock Price, Fair Value and News

0.93USD+0.06 (+6.90%)Market Closed

Market Summary

DNA
USD0.93+0.06
Market Closed
6.90%

DNA Stock Price

View Fullscreen

DNA RSI Chart

DNA Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-2.08

Price/Sales (Trailing)

7.4

EV/EBITDA

-1.12

Price/Free Cashflow

-5.53

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-355.11%

Return on Equity

-81.38%

Return on Assets

-53.61%

Free Cashflow Yield

-18.07%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

251.5M

Rev. Growth (Yr)

-64.64%

Rev. Growth (Qtr)

-37.3%

DNA Earnings

Earnings (TTM)

-892.9M

Earnings Growth (Yr)

-20.65%

Earnings Growth (Qtr)

30.11%

Breaking Down DNA Revenue

Last 7 days

-11.4%

Last 30 days

-14.7%

Last 90 days

-23.1%

Trailing 12 Months

-29.5%

How does DNA drawdown profile look like?

DNA Financial Health

Current Ratio

6.11

DNA Investor Care

Shares Dilution (1Y)

5.78%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023390.0M326.0M315.0M251.5M
2022438.1M539.1M527.9M477.7M
2021136.0M195.2M254.5M313.8M
20200065.4M76.7M
201900054.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ginkgo Bioworks Holdings, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 02, 2024
dmytruk mark e.
sold
-53,727
1.05
-51,169
see remarks
Apr 01, 2024
dmytruk mark e.
acquired
-
-
108,123
see remarks
Mar 04, 2024
dmytruk mark e.
sold
-48,765
1.256
-38,826
see remarks
Mar 01, 2024
dmytruk mark e.
acquired
-
-
85,214
see remarks
Feb 02, 2024
dmytruk mark e.
sold
-47,799
1.208
-39,569
see remarks
Feb 01, 2024
dmytruk mark e.
acquired
-
-
85,208
see remarks
Jan 04, 2024
kelly jason r
sold
-155,500
1.555
-100,000
see remarks
Jan 03, 2024
dmytruk mark e.
sold
-70,522
1.54
-45,794
see remarks
Jan 03, 2024
kelly jason r
sold
-154,400
1.544
-100,000
see remarks
Jan 02, 2024
dmytruk mark e.
acquired
-
-
85,048
see remarks

1–10 of 50

Which funds bought or sold DNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
Clarius Group, LLC
unchanged
-
-9,413
20,603
-%
Apr 17, 2024
Cyndeo Wealth Partners, LLC
added
121
41,017
119,779
0.01%
Apr 16, 2024
Powell Investment Advisors, LLC
sold off
-100
-76,050
-
-%
Apr 16, 2024
Steigerwald, Gordon & Koch Inc.
new
-
11,600
11,600
-%
Apr 16, 2024
Arlington Trust Co LLC
sold off
-100
-1,619
-
-%
Apr 16, 2024
180 WEALTH ADVISORS, LLC
added
0.61
-12,815
29,741
-%
Apr 16, 2024
TSFG, LLC
sold off
-100
-1,000
-
-%
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
added
567
3,072,880
3,931,090
0.10%
Apr 15, 2024
S.A. Mason LLC
unchanged
-
-3,180
6,960
-%
Apr 15, 2024
IAM Advisory, LLC
sold off
-100
-27,885
-
-%

1–10 of 49

Are Funds Buying or Selling DNA?

Are funds buying DNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DNA
No. of Funds

Unveiling Ginkgo Bioworks Holdings, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
knight thomas f. jr.
4.1%
68,328,434
SC 13G/A
Feb 14, 2024
che austin
5.6%
95,898,483
SC 13G/A
Feb 14, 2024
shetty reshma p.
10.5%
188,643,922
SC 13D/A
Feb 14, 2024
kelly jason r
5.0%
85,752,333
SC 13D/A
Feb 14, 2024
viking global investors lp
8.8%
143,085,126
SC 13G/A
Feb 13, 2024
vanguard group inc
8.20%
132,779,676
SC 13G/A
Jan 29, 2024
ark investment management llc
12.26%
198,606,619
SC 13G/A
Jan 29, 2024
baillie gifford & co
14.59%
236,292,183
SC 13G/A
Feb 14, 2023
anchorage capital group, l.l.c.
4.83%
69,904,593
SC 13G/A
Feb 14, 2023
che austin
6.3%
99,857,282
SC 13G/A

Recent SEC filings of Ginkgo Bioworks Holdings, Inc.

View All Filings
Date Filed Form Type Document
Apr 18, 2024
144
Notice of Insider Sale Intent
Apr 17, 2024
144
Notice of Insider Sale Intent
Apr 16, 2024
144
Notice of Insider Sale Intent
Apr 15, 2024
144
Notice of Insider Sale Intent
Apr 12, 2024
144
Notice of Insider Sale Intent
Apr 11, 2024
144
Notice of Insider Sale Intent
Apr 10, 2024
144
Notice of Insider Sale Intent
Apr 09, 2024
144
Notice of Insider Sale Intent
Apr 08, 2024
144
Notice of Insider Sale Intent
Apr 05, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Ginkgo Bioworks Holdings, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.0B
6.8B
-2.93% -28.56%
-8.27
5.69
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.3B
1.8B
-2.14% -28.32%
-41.48
9.99
76.23% 61.08%
17.0B
2.4B
5.64% -9.07%
101.38
7.03
15.42% 18.43%
11.9B
3.7B
-9.46% -28.45%
19.84
3.21
8.87% 75.42%
MID-CAP
5.7B
396.6M
-16.55% -42.15%
-10.83
14.44
425.83% 18.94%
4.4B
-
-12.14% 49.76%
-6.72
60.35
54.84% -34.79%
3.1B
270.6M
-14.48% -8.88%
-13.02
11.51
440.80% -27.84%
2.8B
726.4M
-8.72% -14.74%
-45.89
3.87
40.45% 71.62%
2.8B
240.7M
-18.65% -25.84%
-9.43
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-6.41% -11.48%
25.32
4.54
85.90% -14.05%
544.4M
983.7M
-21.26% -56.58%
-1
0.55
-50.36% 17.16%
382.8M
881.7K
-14.69% 262.26%
-8.58
466.16
-77.61% -5.33%
238.4M
4.9M
-4.49% -3.41%
-1.76
48.98
-54.97% 51.71%
6.2M
2.1M
67.92% 36.92%
-0.23
2.14
-13.45% 66.37%

Ginkgo Bioworks Holdings, Inc. News

Latest updates
MarketBeat12 hours ago
Seeking Alpha28 Mar 202407:00 am
The Motley Fool15 Mar 202407:00 am

Ginkgo Bioworks Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Revenue-37.3%34,755,00055,430,00080,568,00080,702,00098,285,00066,398,000144,618,000168,405,000148,494,00077,610,00043,636,00044,097,00028,699,50013,302,000-
Operating Expenses-37.7%212,872,000341,823,000264,719,000296,447,000329,149,000721,336,000792,397,000843,776,0001,833,229,000104,282,000103,581,000101,212,000-47,715,000-
  S&GA Expenses8.8%89,223,00082,028,000102,341,000111,433,000121,383,000435,221,000438,427,000434,768,000781,626,00028,959,00034,440,00017,927,0005,0009,876,000-
  R&D Expenses-100.0%-156,662,000144,282,000162,639,000177,548,000261,460,000290,059,000323,576,000985,025,00053,021,00052,031,00059,585,000-36,070,000-
EBITDA Margin-35.5%-3.27-2.41-3.52-4.27-4.35-6.61-5.44-5.30-5.76-1.29-1.36-1.04-1.42-1.50-1.97
Interest Expenses-391.8%-43,821,00015,020,00014,349,00014,545,000-8,538,0006,380,0002,264,000-177,0003,854,000-528,000-478,000-475,000-8,293,000-
Income Taxes-800.0%-198,000-22,00067,00082,000-14,770,000-28,000-45,000-184,000-683,000-207,000-431,000-159,000-6,000-
Earnings Before Taxes30.0%-211,892,000-302,913,000-173,248,000-204,887,000-187,848,000-670,159,000-670,615,000-592,777,000-1,605,678,000-102,612,000-54,895,000-74,937,000--26,120,000-
EBT Margin-28.7%-3.55-2.76-3.79-4.44-4.44-6.70-5.51-5.38-5.86-1.41-1.52-1.19-1.63-1.69-2.21
Net Income30.1%-211,694,000-302,891,000-173,315,000-204,969,000-175,468,000-670,131,000-668,825,000-590,505,000-1,600,656,000-101,881,000-53,941,000-73,569,000-5,000-26,055,000-
Net Income Margin-30.6%-3.55-2.72-3.75-4.41-4.41-6.69-5.49-5.36-5.83-1.16-1.15-1.22-1.05-1.68-2.20
Free Cashflow21.4%-61,277,000-77,932,000-87,066,000-110,026,000-130,176,000-41,834,000-108,981,000-23,478,000-170,655,000-10,673,000-58,945,000-70,066,000-19,413,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets-17.8%1,6652,0262,2922,4172,5391,8711,9942,0582,0712,1511,7261,728675697
  Current Assets-12.3%1,0021,1421,2231,3271,4501,4621,5991,7061,7231,8111.003.00427512
    Cash Equivalents-10.0%9441,0491,1061,2061,3161,3031,3771,4931,5501,739236308381495
  Inventory-100.0%-0.000.003.004.006.008.009.003.003.00--3.00-
  Net PPE-6.6%188202294314315188176149146143--12163.00
  Goodwill-15.2%49.0058.0059.0059.0060.0029.0031.0021.0021.0017.00--2.002.00
Liabilities-26.6%568774788810803431427444504533255150205195
  Current Liabilities-2.7%16416816319217312513515913590.005.001.0073.0040.00
Shareholder's Equity-12.4%1,0971,2531,5041,6081,7361,4441,5721,6191,5671,618356396470502
  Retained Earnings-4.2%-5,290-5,078-4,775-4,602-4,397-4,222-3,557-2,888-2,297-697-1015.00-467-341
  Additional Paid-In Capital0.8%6,3866,3346,2816,2126,1365,6695,0984,4713,8052,250106-929-
Shares Outstanding1.4%2,0011,9731,924-1,8921,6311,6211,6071,3601,3021,2911,2901,2751,149
Minority Interest------5.0032.0033.0062.0066.00--9.009.00
Float---2,433---2,392---251---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations21.4%-57.83-73.55-73.53-90.58-104-28.36-99.41-19.90-165-5.23-34.91-48.13---
  Share Based Compensation-18.5%43.0053.0061.0073.00108563607653-0.0015.000.00---
Cashflow From Investing-1280.5%-46.67-3.38-11.22-19.4130.00-46.49-14.66-35.984.00-30.51-23.93-23.05---
Cashflow From Financing-100.6%-0.63-0.31-1.38-0.8998.00-0.39-0.84-1.19-11.041,548-2.12-0.43---
  Buy Backs----------25.00-----

DNA Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Biosecurity revenue:   
Total revenue$ 251,455$ 477,706$ 313,837
Costs and operating expenses:   
Research and development580,6211,052,6431,149,662
General and administrative385,0251,429,799862,952
Impairment of lease assets96,21000
Total operating expenses1,115,8612,686,6582,142,304
Loss from operations(864,406)(2,208,952)(1,828,467)
Other income (expense):   
Interest income57,21720,262837
Interest expense(93)(106)(2,373)
Loss on equity method investments(2,635)(43,761)(77,284)
Loss on investments(54,827)(53,335)(11,543)
Change in fair value of warrant liabilities5,168124,97058,615
Gain on settlement of partnership agreement0023,826
(Loss) gain on deconsolidation of subsidiaries(42,502)31,8890
Other income (expense), net9,1387,634(1,733)
Total other income (expense), net(28,534)87,553(9,655)
Loss before income taxes(892,940)(2,121,399)(1,838,122)
Income tax benefit(71)(15,027)(1,480)
Net loss(892,869)(2,106,372)(1,836,642)
Loss attributable to non-controlling interest0(1,443)(6,595)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders$ (892,869)$ (2,104,929)$ (1,830,047)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders:   
Basic (in dollars per share)$ (0.46)$ (1.25)$ (1.35)
Diluted (in dollars per share)$ (0.46)$ (1.25)$ (1.39)
Weighted average common shares outstanding:   
Basic (in shares)1,944,420,0001,679,061,0001,359,849,000
Diluted (in shares)1,944,420,0001,679,839,0001,360,373,000
Comprehensive loss:   
Net loss$ (892,869)$ (2,106,372)$ (1,836,642)
Other comprehensive loss:   
Foreign currency translation adjustment4,116(917)(1,715)
Total other comprehensive gain (loss)4,116(917)(1,715)
Comprehensive loss(888,753)(2,107,289)(1,838,357)
Cell Engineering revenue   
Biosecurity revenue:   
Total revenue[1]143,531143,666112,989
Product   
Biosecurity revenue:   
Total revenue28,94935,45523,040
Costs and operating expenses:   
Cost of Biosecurity product and service revenue7,48120,64620,017
Service   
Biosecurity revenue:   
Total revenue78,975298,585177,808
Costs and operating expenses:   
Cost of Biosecurity product and service revenue$ 46,524$ 183,570$ 109,673
[1]Includes related party revenue of $22,222, $38,813, and $47,161 for the years ended December 31, 2023, 2022, and 2021, respectively.

DNA Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 944,073$ 1,315,792
Accounts receivable, net17,15780,907
Accounts receivable - related parties7421,558
Prepaid expenses and other current assets39,77751,822
Total current assets1,001,7491,450,079
Property, plant and equipment, net188,193314,773
Operating lease right-of-use assets206,801400,762
Investments78,565112,188
Equity method investments01,543
Intangible assets, net82,741111,041
Goodwill49,23860,210
Other non-current assets58,05588,725
Total assets1,665,3422,539,321
Current liabilities:  
Accounts payable9,32310,451
Deferred revenue (includes $5,426 and $10,309 from related parties)44,48647,817
Accrued expenses and other current liabilities110,051114,694
Total current liabilities163,860172,962
Non-current liabilities:  
Deferred revenue, net of current portion (includes $119,053 and $131,188 from related parties)158,062174,767
Operating lease liabilities, non-current221,835413,256
Warrant liabilities5,70010,868
Other non-current liabilities18,73331,191
Total liabilities568,190803,044
Commitments and contingencies (Note 11)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued00
Common stock, $0.0001 par value (Note 12)199190
Additional paid-in capital6,385,9976,136,378
Accumulated deficit(5,290,528)(4,397,659)
Accumulated other comprehensive income (loss)1,484(2,632)
Total stockholders’ equity1,097,1521,736,277
Total liabilities and stockholders’ equity$ 1,665,342$ 2,539,321
DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEginkgobioworks.com
 INDUSTRYBiotechnology
 EMPLOYEES1292

Ginkgo Bioworks Holdings, Inc. Frequently Asked Questions


What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.? What does DNA stand for in stocks?

DNA is the stock ticker symbol of Ginkgo Bioworks Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ginkgo Bioworks Holdings, Inc. (DNA)?

As of Thu Apr 18 2024, market cap of Ginkgo Bioworks Holdings, Inc. is 1.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers. The fair value of Ginkgo Bioworks Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ginkgo Bioworks Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ginkgo Bioworks Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNA is over valued or under valued. Whether Ginkgo Bioworks Holdings, Inc. is cheap or expensive depends on the assumptions which impact Ginkgo Bioworks Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNA.

What is Ginkgo Bioworks Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, DNA's PE ratio (Price to Earnings) is -2.08 and Price to Sales (PS) ratio is 7.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNA PE ratio will change depending on the future growth rate expectations of investors.